Dipeptidyl Peptidase-4 Inhibitor Versus Sodium-Glucose Cotransporter-2 Inhibitor in the Management of Type 2 Diabetes
Abstract
N/A
J Endocrinol Metab. 2019;9(5):117-119
doi: https://doi.org/10.14740/jem609
		J Endocrinol Metab. 2019;9(5):117-119
doi: https://doi.org/10.14740/jem609


 
  
  
  
  
  Email this article
			Email this article